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Objectives: To evaluate the efficacy of anidulafungin for the treatment of candidaemia and invasive candidiasis
in a large dataset, including patients with deep-seated tissue candidiasis, neutropenia and infection due to non-
albicans Candida species.
Methods:Data were pooled from six prospective, multicentre, multinational studies: four open-label, non-comparative
studies of anidulafungin and two double-blind, double-dummy, randomized studies of anidulafungin versus caspofun-
gin (clinical trial registrations: NCT00496197, NCT00548262, NCT00537329, NCT00689338, NCT00806351 and
NCT00805740; ClinicalTrials.gov). In all studies, patients with culture-confirmed invasive candidiasis received a single
intravenous (iv) loading dose of anidulafungin 200 mg on day 1, followed by 100 mg once-daily. Switch to oral flucona-
zole or voriconazole was permitted after 5–10 days of iv treatment in all studies except one. Antifungal treatment (iv
plus oral therapy if applicable) was maintained for 14 days after the last positive Candida culture. The primary end-
point was successful global response at end of iv therapy (EOivT) in the modified ITT (mITT) population.
Results: In total, 539 patients were included (mITT population). The most common baseline Candida species
were Candida albicans (47.9%), Candida glabrata (21.0%), Candida tropicalis (13.7%), Candida parapsilosis
(13.2%) and Candida krusei (3.5%). Median duration of anidulafungin iv treatment was 10.0 days. The global
response success rate at EOivT was 76.4% (95% CI 72.9%–80.0%). All-cause mortality was 13.0% on day 14 and
19.1% on day 28. Adverse events (AEs) were consistent with the known AE profile for anidulafungin.
Conclusions: These data demonstrate that anidulafungin is effective for treatment of candidaemia and invasive
candidiasis in a broad patient population.
Introduction
Candida species are among the leading causes of invasive fungal
disease worldwide and one of the most common causes of
hospital-acquired bloodstream infections, particularly in patients
with cancer, receiving transplants or in ICUs.1 Invasive candidiasis is
associated with high mortality, ranging from 15% to 25% in adult
patients.2 High mortality is related to several factors, such as lack of
adequate diagnostic assays, associated comorbidities, disease
severity and the Candida species involved.3–8 Although Candida
albicans is the leading cause of invasive candidiasis in most clinical
settings, approximately 50% of patients are now infected with
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non-albicans Candida species.9 The changing epidemiology has
been partly attributed to the selection of less-susceptible Candida
species/strains due to widespread and long-term use of flucona-
zole as a prophylactic and therapeutic agent.10
ESCMID recommends echinocandins as first-line treatment for
patients with systemic candidiasis.11 The 2016 Infectious Diseases
Society of America guidelines also recommend echinocandins as
first-line treatment for candidaemia in both non-neutropenic and
neutropenic patients. Furthermore, echinocandins are recom-
mended as an empirical therapy for suspected invasive candidiasis
in non-neutropenic ICU patients, and for intra-abdominal candi-
diasis.7 Echinocandins are highly active against a range of Candida
species, resistance to them is rare and they are well tolerated, with
similar safety profiles and few drug–drug interactions.12
Anidulafungin is an echinocandin that is approved for candidae-
mia/invasive candidiasis.13,14 However, efficacy data for its use in
patients with deep-seated tissue infections, neutropenia and infec-
tions due to Candida krusei and other non-albicans Candida species
are limited. The registration trial of anidulafungin versus flucona-
zole enrolled too few patients in these groups to generate mean-
ingful data regarding efficacy and excluded patients with C. krusei
infections15 (which are intrinsically resistant to fluconazole), thus
highlighting the need for additional studies in these patients.
In this analysis, patient-level data from six studies were pooled
to assess the efficacy of anidulafungin in a large dataset, including
patients with deep-seated tissue candidiasis, neutropenia and
infections due to C. krusei and other non-albicans Candida species.
Patients and methods
Ethics
All studies are registered with ClinicalTrials.gov and were conducted in com-
pliance with the Declaration of Helsinki and International Conference on
Harmonisation Good Clinical Practice Guidelines. The final protocols, amend-
ments and informed consent documentation were reviewed and approved
by the Institutional Review Boards and Independent Ethics Committees of
the investigational centres. Patients provided written, informed consent.
Study design and treatment
Data were pooled from six prospective, multicentre, multinational studies of
patients with culture-proven candidaemia or invasive candidiasis
(NCT00496197, NCT00548262, NCT00537329, NCT00689338, NCT00806351,
NCT00805740):16–19 four open-label, non-comparative studies, and two
double-blind, double-dummy, randomized studies. The studies had similar
study protocols and endpoints (Table S1, available as Supplementary data at
JAC Online). Patients received intravenous (iv) anidulafungin 200 mg on day
1 followed by 100 mg once-daily. In all studies except one, treatment could
be switched to oral fluconazole or voriconazole after 5 or 10 days of
iv treatment. Antifungal treatment (iv plus oral if used) was maintained for
14 days after the last positive Candida culture.
Patients
Key inclusion criteria
The pooled analysis included data from adult patients with culture-
confirmed candidaemia (positive blood culture) or invasive candidiasis
(positive culture for Candida species from a normally sterile site, or newly
placed drain in a normally sterile site, with or without a positive blood cul-
ture for Candida species) obtained within 96 h prior to the initiation of treat-
ment. Patients could enter studies based on microbiological evidence
suggestive of Candida infection (e.g. positive blood or tissue specimen cul-
ture positive for yeast); however, confirmation of Candida species was
required within 96 h to remain in the study. Patients were required to have
clinical signs and symptoms of systemic Candida infection, such as: fever,
hypothermia or hypotension within 48 h before starting treatment; local-
ized signs and symptoms of inflammation at a site infected with Candida
species; or radiological findings suggestive of invasive candidiasis.
In the pooled database, patients were identified as neutropenic if they
had a baseline absolute neutrophil count (ANC) of 500 cells/lL or a total
white blood cell (WBC) count of500 cells/lL, or if they had been classified
as neutropenic at baseline by the investigators.
Key exclusion criteria
Patients were excluded if they: received .48 h of prior antifungal therapy;
had at infection sites prosthetic devices or vascular catheters (including
central venous catheters) that could not be removed prior to or within 24–
48 h of study entry; or had previously failed treatment for the current epi-
sode of candidaemia or invasive candidiasis.
Objectives/study endpoints
The purpose of the analysis was to determine the efficacy of anidulafungin
for the treatment of candidaemia and invasive candidiasis in a large data-
set, including patients with deep-seated tissue candidiasis, neutropenia
and infections due to C. krusei and other non-albicans Candida species.
The ITT population comprised all patients who received1 dose of ani-
dulafungin and was used for the safety analysis. The modified ITT (mITT)
population comprised all patients in the ITT population with candidaemia/
culture-confirmed invasive candidiasis who received 1 dose of anidula-
fungin, and was used for the efficacy analysis.
Efficacy endpoints
The primary efficacy endpoint was global response at end of iv therapy
(EOivT) in the mITT population. A global response was considered success-
ful if there was both clinical success (resolution of signs and symptoms of
candidaemia/invasive candidiasis and no need for additional systemic anti-
fungal therapy for Candida infection) and microbiological success (eradica-
tion of Candida species present at baseline, as determined on follow-up
culture, or presumed eradication where follow-up culture samples could
not be obtained for a patient with a successful clinical response). Global
response at end of treatment (EOT) in the mITT population and all-cause
mortality on days 14 and 28 after the first administration of study drug
(ITT and mITT populations) were secondary endpoints.
Safety and tolerability endpoints
Safety was a secondary endpoint. Adverse events (AEs; occurring during
active treatment or within 30 days of the last dose of treatment) and seri-
ous AEs (SAEs) were collected from all studies and summarized by Medical
Dictionary for Regulatory Activities (MedDRA)-preferred term. Treatment-
related AEs were based on the investigators’ judgement.
Statistical analysis
No hypotheses for efficacy endpoints were tested. Success rates for global
response were estimated with 95% CIs for binomial proportion using the
Clopper–Pearson method. In the efficacy analysis, indeterminate or missing
data were considered failures.
Multivariate logistic regression was used to identify independent predic-
tors significantly related to failures. The following continuous variables
were included in the model: age, weight and baseline APACHE II score.
Dichotomous variables were: neutropenia; sex; broad-spectrum antibiotic
use; central venous catheter use; ICU stay 4 days; total parenteral
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nutrition; surgery or abdominal surgery; mechanical ventilation; renal insuf-
ficiency/failure/dialysis; use of systemic steroids or other immunosuppres-
sive agents; chemotherapy; and presence of multiple baseline pathogens.
Results
Patients
Across the six studies, 636 patients received 1 dose of anidula-
fungin (ITT population; Figure 1). Among these, 539 patients had
culture-confirmed candidaemia or invasive candidiasis at baseline
or within 96 h of treatment initiation (mITT population).
Patient demographics and baseline characteristics in the mITT
population are presented in Table 1. Most patients were male, with
a mean age of 57.5 years, and had a median (range) APACHE II
score of 15.0 (2–44). The most frequently isolated Candida species
at baseline was C. albicans (47.9%), followed by Candida glabrata
(21.0%), Candida tropicalis (13.7%), Candida parapsilosis (13.2%)
and C. krusei (3.5%). Overall, 496 (92.0%) patients had one
Candida species recovered at baseline and 43 (8.0%) patients had
.1 Candida species recovered at baseline.
The median (range) duration of anidulafungin iv treatment was
10.0 (1–42) days, with a median (range) duration of overall ther-
apy (iv and oral) of 15.0 (1–67) days. Details on switching to oral
therapy are given in Table 2.
Efficacy
The global response success rate at EOivT was 76.4% (95% CI
72.9%–80.0%), with a clinical success rate of 80.3% (95% CI
77.0%–83.7%) and a microbiological success rate of 82.4%
(95% CI 79.2%–85.6%) (Figure 2a).
Global response success rates at EOivT varied by pathogen and
are shown in Figure 3(a). Similar findings were observed for global
response success rates at EOT (Table S2). All-cause mortality in the
Patients screened
N = 658
Did not receive ≥1 dose of
anidulafungin (n = 22)
Did not have C/IC confirmed
at baseline (n = 97)
Patients analysed in the
pooled database
• Deep-seated tissue infection
  (n = 129)
• Neutropenic (n = 46)
• With ≥1 non-albicans
  Candida infection (n = 312)
• C. krusei infections (n = 19)
Safety population
N = 636
Anidulafungin only (n = 378)
Anidulafungin → oral fluconazole (n = 157)
Anidulafungin → oral voriconazole (n = 101)
mITT population
N = 539
Anidulafungin only (n = 302)
Anidulafungin → oral fluconazole (n = 145)
Anidulafungin → oral voriconazole (n = 92)
Follow-up
Patients who completed all study visits (n = 299)a
Patients who did not complete all study visits:
      Patients withdrawn due to death (n = 152)b
      Other reasons for early discontinuation from study (n = 185)
Related to study drug: insufficient microbiological response (n = 21),
AE (n = 10), insufficient clinical response (n = 4), other (n = 1)
Not related to study drug: AE (n = 21), did not meet entry criteria
(n = 32), lost to follow-up (n = 23), withdrawal of participation (n = 20),
no pathogen isolated from pre-treatment specimen (n = 4),
other (n = 26), protocol violation (n = 23)
Figure 1. Patient disposition. AE, adverse event; C/IC, candidaemia or invasive candidiasis; mITT, modified ITT. aPatients who completed all visits as
described in the respective protocols. bIn the period from the first dose of study medication until the end of study follow-up visit.
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mITT population was 13.0% (n"70/539) on day 14 and 19.1%
(n"103/539) on day 28.
Patients with deep-seated tissue candidiasis
A total of 129 patients with microbiologically confirmed deep-
seated tissue candidiasis of 1 organs, with or without concomi-
tant candidaemia, were analysed. Patients had a mean (SD) age of
60.2 (16.6) years and a median (range) APACHE II score of 15.0
(2–44).
The most frequently isolated Candida species at baseline were
C. albicans (64.3%), C. glabrata (31.0%), C. tropicalis (11.6%) and
C. krusei (5.4%). Sixteen (12.4%) patients had multiple Candida
species recovered at baseline. The sites of infection were intra-
abdominal (n"107; 82.9%), pleural cavity (n"7; 5.4%), kidney
(n"5; 3.9%), lung (n"4; 3.1%), bone (n"2; 1.6%), eye (n"2;
1.6%), skin/soft tissue (n"2; 1.6%) and other sites (n"5; 3.9%).
Of these 129 patients, 21 (16.3%) had concomitant candidaemia.
The median (range) duration of iv anidulafungin treatment was
14.0 (1–42) days and the median (range) duration of overall ther-
apy (iv and oral) was 16.0 (1–56) days. The global response success
rate at EOivT was 79.1% (95% CI 72.0%–86.1%) (Figure 2b). Global
response success rates at EOivT varied by pathogen, with the high-
est response rates observed in patients with infections due to
C. glabrata (80.0%; 95% CI 67.6%–92.4%) and C. albicans (79.5%;
95% CI 70.8%–88.2%) (Figure 3b). All-cause mortality in the mITT
population was 14.7% (n"19/129) on day 14 and 20.2%
(n"26/129) on day 28.
Patients with neutropenia
Overall, 46 neutropenic patients were identified (mITT population)
based on an ANC of 500 cells/lL or a WBC of 500 cells/lL, or if
they had been classified as neutropenic by the investigators at
baseline.
Most patients were white (n"33; 71.7%) and male (n"28;
60.9%), with a mean age of 56.0 years. Among patients with ANC
or WBC available at baseline and throughout the treatment period
(n"28), median (range) duration of neutropenia was 16.0 (1–43)
days. Coexisting conditions in 46 neutropenic patients included
leukaemia (n"21; 45.7%), lymphoma (n"11; 23.9%), plasma
cell disorder [plasma cell myeloma or plasmacytoma (n"6;
13.0%)], solid tumour (n"7; 15.2%) and bone marrow transplant
(n"4; 8.7%). There were 58 Candida strains isolated at baseline in
the 46 neutropenic patients (16 C. tropicalis; 9 C. krusei; 8 C. parapsi-
losis; 7 C. albicans; 7 C. glabrata; 4 Candida keyfr; 2 Candida ciferrii; 2
Candida famata; 1 Candida dubliniensis; 1 Candida guilliermondii
and 1 Candida norvegensis).
Nine (19.6%) patients had multiple Candida species recovered
at baseline.
The median (range) duration of anidulafungin iv treatment was
11.5 (1–42) days and the median duration of overall therapy (iv
and oral) was 16.0 (1–67) days. Overall, 16 patients (34.8%)
switched from iv to oral therapy (7 patients to fluconazole and 9 to
voriconazole). The median (range) duration of oral therapy was
11.5 (6–38) days.
The global response success rate at EOivT was 56.5% (95% CI
42.2%–70.8%) (Figure 2b). Among patients with ANC or WBC avail-
able at baseline visit, throughout the study treatment period and
Table 1. Patient demographics and baseline characteristics (mITT
population)
Characteristic Total (N"539)
Sex, n (%)
male 297 (55.1)
Age, years
mean (SD) 57.5 (16.3)
range 18–91
White/Black/Asian/other/not specified, % 69.0/10.9/12.4/6.1/1.5
Weight, kg
mean (SD) 74.4 (21.6)
range 32.0–240.0
Baseline APACHE II score (N"536)
mean (SD) 14.9 (6.2)
median 15.0
range 2–44
APACHE II score 20, n (%) 435 (80.7)
APACHE II score .20, n (%) 101 (18.7)
Risk factors for invasive candidiasis, n (%)a
broad-spectrum antibiotics 421 (88.4)
central venous catheter 377 (79.2)
length of ICU stay 4 days 236 (49.6)
total parenteral nutrition 215 (45.2)
surgery 213 (44.7)
mechanical ventilation 197 (41.4)
abdominal surgery 192 (40.3)
renal failure 151 (31.7)
otherb 125 (26.3)
use of systemic steroids or other
immunosuppressants
120 (25.2)
anticancer chemotherapy 67 (14.1)
neutropeniac 43 (9.0)
solid organ transplant 28 (5.9)
Baseline pathogen, n (%)a
Candida albicans 258 (47.9)
Candida glabrata 113 (21.0)
Candida tropicalis 74 (13.7)
Candida parapsilosis 71 (13.2)
Candida krusei 19 (3.5)
Candida kefyr 6 (1.1)
Candida dubliniensis 5 (0.9)
Candida guilliermondii 4 (0.7)
Candida famata 3 (0.6)
Candida lusitaniae 3 (0.6)
Candida pelliculosa 3 (0.6)
Candida norvegensis 2 (0.4)
Candida rugosa 1 (0.2)
Baseline site of infection, n (%)
blood only 408 (75.7)
non-blood sterile site only 111 (20.6)
blood and non-blood sterile site 20 (3.7)
mITT, modified ITT.
aPatients may be counted in.1 category.
b‘Other’ risk factors included: mucosal colonization (n"52); immunosup-
pressive therapy (n"23); diabetes (n"8); and other recorded risk fac-
tors (n"49).
cForty-three patients had neutropenia as a risk factor at baseline as
reported by the investigator in the case report form, and did not neces-
sarily correspond to the 46 patients identified as neutropenic in the
pooled database as per the definition in the inclusion criteria.
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at EOT visit, the global response success rate at EOivT in patients
with persistent neutropenia was 53.8% (n"7/13; 95% CI
26.7%–80.9%) versus 80.0% (n"12/15; 95% CI 59.8%–100.0%)
among patients who had resolved neutropenia. Global response
success rates at EOivT by pathogen are shown in Figure 3(c).
All-cause mortality in the mITT population was 19.6%
(n"9/46) on day 14 and 23.9% (n"11/46) on day 28.
Patients with infections due to non-albicans
Candida species
A total of 312 patients had infection due to 1 non-albicans
Candida species, of whom 269 were infected by a single non-
albicans Candida strain. Patient demographics and baseline char-
acteristics for the most commonly isolated baseline Candida
species are presented in Table S3. Of infections due to non-albicans
Candida species, most were due to C. glabrata (n"113/312;
36.2%), followed by C. tropicalis (n"74/312; 23.7%) and
C. parapsilosis (n"71/312; 22.8%). In vitro susceptibility to anidu-
lafungin was 100% for all Candida species except C. parapsilosis
(86.7%) (Table S4). MICs of anidulafungin were higher for C. para-
psilosis compared with other Candida species.
Among patients infected by non-albicans Candida species,
global response success rates at EOivT by main pathogen are
shown in Figure 3(a). The global response success rate at EOivT
was 75.8% (n"204/269) in patients infected by a single non-
albicans Candida species versus 74.2% (n"23/31) in patients with
mixed C. albicans and non-albicans Candida species. In patients
with infection due to 2 non-albicans Candida species, the global
response success rate at EOivT was 66.7% (n"8/12) (Table 3).
All-cause mortality in the monomicrobial and polymicrobial
mITT population is presented in Table 3.
Patients with infection due to C. krusei
In total, 19 patients with C. krusei infection were identified.
At baseline, 57.9% of patients (n"11/19) were candidaemic while
42.1% (n"8/19) were neutropenic (,500 cells/lL). Median
(range) APACHE II score was 16.0 (5–24). Patient demographics
and baseline characteristics are presented in Table S3. All C. krusei
isolates were susceptible to anidulafungin in vitro. The global
Table 2. Duration and time to switch to oral therapy for all patients (modified ITT population)
All patients with switch permitteda (N"515)
switch permitted after5 daysb (N"334) switch permitted after10 daysc (N"181)
Patients switching to oral therapy, n (%) 173 (51.8) 63 (34.8)
Duration of oral therapy, days
median 6.0 14.0
mean 8.0 16.6
range 5–28 11–38
Time to switch to oral therapy, days
median 5.0 13.0
mean 7.0 15.5
range 4–27 7–37
Patients switching to voriconazole therapy, n (%) 76 (22.8) 16 (8.8)
Duration of voriconazole therapy, days
median 7.0 13.5
mean 8.6 17.1
range 5–28 11–38
Time to switch to voriconazole therapy, days
median 6.0 12.0
mean 7.5 16.0
range 4–27 10–37
Patients switching to fluconazole therapy, n (%) 97 (29.0) 47 (26.0)
Duration of fluconazole therapy, days
median 6.0 14.0
mean 7.6 16.4
range 5–25 11–35
Time to switch to fluconazole therapy, days
median 5.0 13.0
mean 6.5 15.3
range 4–24 7–34
aIn study A8851022, switch to oral therapy was not permitted and 24 patients were not included in this table.
bStudies A8851011, A8851015 and A8851016.
cStudies A8851019 and A8851021.
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response success rate at EOivT was 73.7% (95% CI 53.9%–93.5%)
(Figure 3a).
All-cause mortality in the mITT population was 5.3% (n"1/19)
on both days 14 and 28.
Multivariate logistic regression
In the multivariate logistic regression analysis of the global popula-
tion, neutropenia [odds ratio (OR) 2.6; 95% CI 1.1–6.2], and higher
APACHE II scores (OR 1.1; 95% CI 1.0–1.1) were identified as fac-
tors associated with global response of failure (Table S5).
Safety
A total of 636 patients received treatment with anidulafungin.
At least one AE was reported in 554 patients (87.1%). The most
frequently reported AEs were in the categories of infections
(40.6%), gastrointestinal disorders (34.0%), and respiratory,
thoracic and mediastinal disorders (28.6%). The most common
(5%) AEs by MedDRA-preferred term were diarrhoea (10.2%),
hypokalaemia (9.0%), pyrexia (8.6%), hypotension (8.0%), sep-
tic shock (7.1%), nausea (6.9%), vomiting (6.4%), anaemia
(6.1%) and hypertension (5.8%). Most AEs were mild or moder-
ate in severity. There were 192 reported treatment-related AEs
in 99 (15.6%) patients and most were mild or moderate.
Ten (1.6%) patients discontinued therapy due to treatment-
related AEs.
A total of 527 SAEs occurred in 301 patients. The most common
categories were infections and infestations (18.7%), respiratory,
thoracic and mediastinal disorders (9.4%), cardiac disorders
(8.6%), general disorders and administration-site conditions
(7.5%), and gastrointestinal disorders (6.9%).
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Figure 2. (a) Global, clinical and microbiological response success rates in all patients at end of intravenous therapy (EOivT); and (b) global response
success rates at EOivT in patients with deep-seated tissue infection and neutropenic patients (mITT population).
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No new safety concerns were identified in the overall pooled
population or in any of the patient subgroups analysed.
All-cause mortality in the ITT population was 13.2%
(n"84/636) on day 14 and 19.3% (n"123/636) on day 28.
Discussion
This patient-level pooled analysis of six studies evaluated the effi-
cacy of anidulafungin for the treatment of candidaemia and inva-
sive candidiasis in all patients and in subgroups with deep-seated
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Figure 3. Global response success rates at end of intravenous therapy stratified by main baseline pathogen (patients could have more than one
Candida species at baseline) in (a) all patients, (b) patients with deep-seated tissue candidiasis and (c) neutropenic patients.
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tissue infections, neutropenia and infections due to non-albicans
Candida species, including C. krusei. We believe these data repre-
sent the largest collection of patients in special populations with
Candida infection and treated with the same iv antifungal drug
(anidulafungin) in a clinical trial setting.
Anidulafungin alone (iv), or followed by a switch to oral flucona-
zole/voriconazole, was effective for candidaemia and invasive can-
didiasis in all study populations. The overall global response rate at
EOivT (76.4%) was similar to that reported in the anidulafungin
registration study (75.6%),15 despite the shorter duration of iv
therapy and earlier transition to oral therapy in this pooled analy-
sis. This was also similar to the EOivT success rate reported in the
caspofungin registration trial (73.4%).20 C. albicans and C. glabrata
were still the most common baseline pathogens in the current
analysis, similar to the epidemiological findings reported in the ani-
dulafungin registration study.15 In contrast, C. tropicalis was the
most commonly recovered baseline pathogen in patients with
neutropenia (34.8%).
In patients with deep-seated tissue candidiasis, the global
response success rate at EOivT (79.1%) was high and consistent
with the registration study (75.6%).15
The global response success rates of anidulafungin in patients
with neutropenia were also comparable to those found in other
studies.20–22 Rates of successful global response at EOivT in
patients with resolved neutropenia (80.0%) and persistent neutro-
penia (53.8%) were similar to those reported for micafungin in sim-
ilar patients (75.0% and 50.0%, respectively).21 These data,
together with the multivariate analysis, support the well-known
concept that outcomes in persistently neutropenic patients are
typically worse than in patients without neutropenia.
The global response success rate in patients with C. albicans
was 77.5%, consistent with the rate reported in the registration
study (81.1%).15 Previous studies have reported that anidulafungin
may be less potent for the treatment of C. glabrata;23–25 however,
in this study, the global response rate was 78.8%. Response rates
among patients with infection due to C. tropicalis and C. krusei
were 66.2% and 73.7%, respectively.
Consistent with previous studies, MICs in this study
were higher for C. parapsilosis versus other Candida spe-
cies.7,26–31 Data on the effectiveness of echinocandins against
C. parapsilosis are limited.15,20–22 Furthermore, C. parapsilosis
has been associated with higher persistence and breakthrough
rates among patients receiving an echinocandin.1 The results
of this analysis show that anidulafungin had a success rate of
77.5%, comparable with that observed in patients with infec-
tion due to C. albicans.
The efficacy of anidulafungin in patients with infections due to
different non-albicans Candida species was similar to that of cas-
pofungin in a pooled analysis.32 C. krusei is intrinsically resistant to
fluconazole, and echinocandins appear to be the most active
against this important pathogen.33,34 In the anidulafungin regis-
tration trial the patients infected with C. krusei had to be excluded
because fluconazole was used as comparator.15 The present data-
set is the largest to provide prospectively collected information on
the efficacy of anidulafungin against C. krusei.
We demonstrate for the first time that anidulafungin is effec-
tive for the treatment of patients with infection due to C. krusei
with a success rate of 73.7% at EOivT and where 42.1% of patients
were neutropenic. In addition, the present study reports on the
largest prospectively collected set of patients with infection due to
C. glabrata, which may exhibit resistance to both azoles and echi-
nocandins.35 We demonstrate a success rate of anidulafungin of
78.8%, which is not significantly different from that for C. albicans
infections in the same pooled dataset.
AEs were mostly mild or moderate in severity, and consistent
with the known safety profile of anidulafungin in adult patients
with invasive candidiasis/candidaemia, with no new safety con-
cerns identified.
Limitations to this analysis were that four studies were open
label and conducted at various sites and centres, and at differ-
ent times. In addition, the two double-blind, double-dummy,
randomized studies of anidulafungin versus caspofungin
included in the present analysis have not been peer-reviewed
and published previously. Furthermore, this was a post hoc
analysis.
In conclusion, response to anidulafungin in this large dataset of
patients with invasive candidiasis/candidaemia was consistent
with previously reported data, supporting registration trial findings.
Anidulafungin is effective for the treatment of invasive candidiasis/
candidaemia (including deep-seated tissue candidiasis), infections
in patients with neutropenia and infections due to non-albicans
Candida species.
Table 3. Distribution of patients with infections caused by a single or multiple Candida isolates, at baseline, global response at end of intravenous
therapy (EOivT) and all-cause mortality (days 14 and 28) in the modified ITT (mITT) population (N"539)
Patients with Candida infection at baseline Global response at EOivT, n (%); 95% CI
All-cause mortality, n (%)
day 14 day 28
Patients with single Candida isolate, n (%) 496 (92.0)
C. albicans, n (%) 227 (45.8) 177 (78.0); 72.6%–83.4% 32 (14.1) 44 (19.4)
C. non-albicans, n (%) 269 (54.2) 204 (75.8); 70.7%–81.0% 33 (12.3) 51 (19.0)
Patients with multiple Candida isolates 43 (8.0)
C. albicans and1 C. non-albicans 31 (72.1) 23 (74.2); 58.8%–89.6% 3 (9.7) 6 (19.4)
.1 C. non-albicans 12 (27.9) 8 (66.7); 40.0%–93.3% 2 (16.7) 2 (16.7)
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